Citius Oncology, a subsidiary of Citius Pharmaceuticals, has signed an exclusive distribution agreement with Unipha to make Lymphir (denileukin diftitox-cxdl) available outside the USA. This marks Citius Oncology’s third international distribution partnership, expanding global access for their targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Lymphir is intended for Stage I-III CTCL cases after at least one prior systemic therapy.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Citius inks EU distribution agreement for CTCL treatment
Citius Oncology, a subsidiary of Citius Pharmaceuticals, has signed an exclusive distribution agreement with Unipha to make Lymphir (denileukin diftitox-cxdl) available outside the USA. This marks Citius Oncology’s third international distribution partnership, expanding global access for their targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Lymphir is intended for Stage I-III CTCL cases after at least one prior systemic therapy.